J Clin Oncol 2021 Aug 2
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Related Questions
How do you sequence targeted therapy and immunotherapy in patients with metastatic lung adenocarcinoma with EGFR exon 20 insertion mutations?
4 Answers
Mednet Member
Medical Oncology · Fox Chase Cancer Center
EGFR insertion 20 mutations are a rare subset of adenocarcinoma (1-2%). Patients with disease characterized by these mutations do not respond to EGFR TKIs such as osimertinib. Until recently, the standard first-line therapy for such patients was chemotherapy alone, typically carboplatin/pemetrexed. ...
How do you handle Grade 3-4 standard infusion reactions with Amivantamab?
1
1 AnswersMednet Member
Medical Oncology · Georgetown University Hospital
Fortunately, G3+ infusion reactions with amivantamab are uncommon. In the CHYSALIS phase I study which led to approval for EGFR exon 20 (Park et al., PMID 34339292), G3+ infusion reactions were only seen in 3% of patients. But grade 1-2 infusion reactions were fairly common.Infusion reactions tend t...